US20040072809A1 - Ophthalmologic irrigation solutions and method - Google Patents
Ophthalmologic irrigation solutions and method Download PDFInfo
- Publication number
- US20040072809A1 US20040072809A1 US10/630,626 US63062603A US2004072809A1 US 20040072809 A1 US20040072809 A1 US 20040072809A1 US 63062603 A US63062603 A US 63062603A US 2004072809 A1 US2004072809 A1 US 2004072809A1
- Authority
- US
- United States
- Prior art keywords
- agents
- solution
- millimolar
- group
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/08—Mydriatics or cycloplegics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to surgical irrigation solutions and methods, and particularly to irrigation solutions for use during ophthalmologic procedures.
- Ophthalmologic surgery typically requires the use of a physiologic irrigation solution to protect and maintain the physiological integrity of intraocular tissues.
- ophthalmologic surgical procedures usually requiring irrigation solutions are cataract operations, corneal transplant operations, vitreoretinal operations and trabeculectomy operations for glaucoma.
- Solutions that have been used in ophthalmologic surgical irrigation include normal saline, lactated Ringer's solution and Hartmann's lactated Ringer's solution, but these are not optimal due to potential unfavorable corneal and endothelial effects.
- Other aqueous solutions that include agents such as electrolytes, buffering agents for pH adjustment, glutathione and/or energy sources such as dextrose, better protect the tissues of the eye, but do not address other physiologic processes associated with surgery.
- One commonly used solution for ophthalmologic irrigation is a two part buffered electrolyte and glutathione solution disclosed in U.S. Pat. No.
- a topical ophthalmologic solution is disclosed in U.S. Pat. No. 5,811,446 to Thomas that includes histidine, and which may include at least one other active agent such as an anti-glaucoma agent, such as timolol or phenylephrine, a steroid or an NSAID.
- This reference teaches application of the composition to limit the inflammation associated with ophthalmic procedures.
- the solution is administered by a dropper into the cul-de-sac of the eye.
- U.S. Pat. No. 5,624,893 to Yanni includes compositions including a wound healing agent, such as a steroid or a growth factor, and/or a pain mediator, such as an NSAID, a bradykinin antagonist, or a neurokinin-1 antagonist.
- a wound healing agent such as a steroid or a growth factor
- a pain mediator such as an NSAID, a bradykinin antagonist, or a neurokinin-1 antagonist.
- the compositions are intended for the treatment and prevention of corneal haze associated with laser irradiation and photoablation.
- ocular drug delivery Various methods of ocular drug delivery are conventionally employed, each of which has limitations. These limitations may include corneal and conjuctival toxicity, tissue injury, globe perforation, optic nerve trauma, central retinal artery and/or vein occlusion, direct retinal drug toxicity, and systemic side effects. For example, topical medications applied drop-wise are frequently impeded in reaching a targeted ocular site due to the eye's natural protective surface. In many situations, a rather small percentage of the medication applied to the surface of the eye will actually reach the desired therapeutic site of action.
- One difficulty in ocular drug delivery during surgical procedures is to achieve the desired therapeutic concentration levels with the proper temporal control.
- the most desired pharmacokinetic effect is to be able to rapidly achieve a therapeutic concentration range and subsequently maintain the drug concentration at a constant level. This is not achieved by conventional methods of ocular drug delivery.
- the challenge of achieving similar pharmacokinetic profiles is substantially compounded when it is desirable to simultaneously deliver more than one drug.
- a unique group of factors affect the ability of a drug to penetrate the corneal epithelia, including the size of the molecule, its chemical structure and its solubility characteristics.
- the present invention provides solutions for local ocular delivery of multiple active agents that act on a plurality of differing molecular targets to perioperatively inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or to decrease intraocular pressure.
- the solutions and methods of the present invention use at least first and second therapeutic agents that are selected from the physiologic functional classes of anti-inflammatory agents, analgesic agents, mydriatic agents and agents for decreasing intraocular pressure (“IOP reducing agents”), the second agent providing at least one physiologic function different than a function or functions provided by the first agent.
- the solutions are preferably applied by continuous irrigation of ocular tissues at the site of surgery during a majority of the operative procedure.
- Solutions of this aspect of the present invention may include: (a) one or more anti-inflammatory agents in combination with one or more analgesic agents, and optionally may also include one or more IOP reducing agents and/or mydriatic agents; (b) one or more anti-inflammatory agents in combination with one or more IOP reducing agents, and optionally one or more analgesic and/or mydriatic agents; (c) one or more anti-inflammatory agents in combination with one or more mydriatic agents, and optionally one or more analgesic agents and/or IOP reducing agents; (d) one or more analgesic agents in combination with one or more IOP reducing agents, and optionally one or more anti-inflammatory agents and/or mydriatic agents; (e) one or more analgesic agents in combination with one or more mydriatic agents, and optionally one or more anti-inflammatory agents and/or IOP reducing agents; or (f) one or more mydriatic agents in combination with one or more IOP reducing
- the present invention provides a solution constituting a mixture of multiple agents in low concentrations directed at inhibiting locally the mediators of pain, inflammation, reducing intraocular pressure and/or causing mydriasis, in a physiologic electrolyte carrier fluid.
- the invention also provides a method for perioperative delivery of the irrigation solution containing these agents directly to a surgical site, where it works locally at the receptor and enzyme levels to preemptively limit pain and inflammation, reduce intraocular pressure and/or cause mydriasis, at the site.
- a desired therapeutic effect can be nearly instantaneously achieved with lower doses of agents than are necessary when employing systemic methods of delivery (e.g., intravenous, intramuscular, subcutaneous and oral) or by injection.
- systemic methods of delivery e.g., intravenous, intramuscular, subcutaneous and oral
- concentrations of agents utilized may be lower than if the agents were applied drop-wise in a single application or by intraocular injection.
- the present invention has several advantages over other types of compositions and methods for delivery of active agents during intraocular surgery.
- Liquid compositions for topical drop-wise instillation of a pharmaceutical agent to the eye do not always provide an accurate method for delivering a defined dosage, because portions of the drop are either blinked away or drain away during administration.
- subsequent use of a normal irrigation solution can be anticipated to effectively dilute and remove a dose delivered drop-wise delivered to the eye during an intraocular or topical ophthalmologic procedure before the start of the surgical procedure, thereby reducing the therapeutic efficacy of the agent.
- the increased time over which the drugs can be delivered in accordance with the present invention via irrigation during an intraocular or topical ophthalmologic procedure allows a lower concentration of the drugs to be used in the irrigation solution, which reduces the risk of ocular toxicity. Due to pharmacokinetic considerations, doses of agents delivered only pre-operatively will exhibit a variable concentration and efficacy as a function of time, reaching a peak of effectiveness some time after the initial application, then subsequently declining in efficacy due to a progressively decreasing concentration.
- the particular pharmacokinetic parameters after topical instillation of a drug will vary for each drug depending on the solubility characteristics of the agent, the vehicle composition, and the pH, osmolality, tonicity and viscosity of the formulation.
- One advantage of the invention is that the irrigation solutions provided maintain a constant concentration of active agents at the ocular surgery site, thereby maintaining a constant therapeutic effect.
- the present invention provides for controlled, site-specific drug delivery to the eye for the dual purposes of increasing efficacy and decreasing side effects of ocular therapy.
- a therapeutic concentration range is rapidly achieved, and is subsequently maintained at an effectively constant level during the period of irrigation.
- the present invention also provides a method for manufacturing a medicament compounded as a dilute irrigation solution for use in continuously irrigating an operative site or wound during an operative procedure.
- the method entails dissolving in a physiologic electrolyte carrier fluid a plurality of analgesic agents, anti-inflammatory agents, mydriatic agents, and/or agents that decrease intraocular pressure (“IOP reducing agents”), each agent included at a concentration of preferably no more than 100,000 nanomolar, and more preferably no more than 10,000 nanomolar, except for local anesthetics, which may be applied at a concentration of no more than 100,000,000 nanomolar, preferably no more than 10,000,000 nanomolar, more preferably no more than 1,000,000 nanomolar, and still more preferably no more than 100,000 nanomolar.
- IOP reducing agents each agent included at a concentration of preferably no more than 100,000 nanomolar, and more preferably no more than 10,000 nanomolar, except for local anesthetics, which may be applied at a concentration
- the method of the present invention provides for the delivery of a dilute combination of multiple receptor antagonists and agonists and enzyme inhibitors and activators directly to a wound or operative or procedural site of the eye, during surgical, therapeutic or diagnostic procedures for the inhibition of pain and inflammation, reduction or control of intraocular pressure, and/or the promotion of mydriasis.
- the active ingredients in the solution are being locally applied directly to the ocular tissues in a continuous fashion during the procedure, the drugs may be used efficaciously at extremely low doses relative to those doses required for therapeutic effect when the same drugs are delivered systemically (e.g., orally, intramuscularly, subcutaneously or intravenously), or in a single application such as drop-wise or by intraocular injection.
- the term “local” encompasses application of a drug in and around a wound or other operative or procedural site, and excludes oral, subcutaneous, intravenous and intramuscular administration.
- irrigation is intended to mean the flushing of a wound or anatomic structure with a stream of liquid.
- continuous encompasses uninterrupted application, repeated application at frequent intervals at a frequency sufficient to substantially maintain a predetermined therapeutic local concentration of the applied agents, and applications which are uninterrupted except for brief cessations such as to permit the introduction of other drugs or procedural equipment or due to operative technique, such that a substantially constant predetermined therapeutic local concentration is maintained locally at the wound or operative site.
- wound As used herein, the term “wound”, unless otherwise specified, is intended to include surgical wounds, operative/interventional sites and traumatic wounds.
- operative and “procedural”, unless otherwise specified, are each intended to include surgical, therapeutic and diagnostic procedures.
- the irrigation solution including selected therapeutic agents is locally and perioperatively applied to ocular tissues of the operative site, e.g., intraocularly for intraocular procedures and to the exterior of the eye for superficial procedures.
- perioperative encompasses application intraprocedurally, pre- and intraprocedurally, intra- and postprocedurally, and pre-, intra- and postprocedurally.
- the solution is applied preprocedurally and/or postprocedurally as well as intraprocedurally.
- the irrigation solution is most preferably applied to the wound or surgical site prior to the initiation of the procedure, or before substantial tissue trauma, and continuously throughout the duration of the procedure, to preemptively block pain and inflammation, inhibit intraocular pressure increases, and/or cause mydriasis.
- continuous irrigation is delivered throughout a substantial portion of the procedure, before and during the majority of operative trauma, and/or during the period when mydriasis may be required and/or control of intraocular pressure may be required.
- local administration guarantees a known concentration at the target site, regardless of interpatient variability in metabolism, blood flow, etc.; (2) because of the direct mode of delivery, a therapeutic concentration is obtained nearly instantaneously and, thus, improved dosage control is provided; and (3) local administration of the active agents directly to a wound or operative site also substantially reduces degradation of the agents through extracellular processes, e.g., first- and second-pass metabolism, that would otherwise occur if the agents were given systemically (e.g., orally, intravenously, subcutaneously or intramuscularly). This is particularly true for those active agents that are peptides, which are metabolized rapidly. Thus, local administration permits the use of compounds or agents which otherwise could not be employed therapeutically. Local, continuous delivery to the wound or operative site minimizes drug degradation or metabolism while also providing for the continuous replacement of that portion of the agent that may be degraded, to ensure that a local therapeutic concentration, sufficient to maintain receptor occupancy, is maintained throughout the duration of the operative procedure.
- inflammatory mediators and processes are preemptively inhibited in accordance with the present invention before they can exert tissue damage, and the mediators of increases in intraocular pressure are likewise preemptively inhibited, the benefit is more substantial than if given after these processes have been initiated.
- the irrigation solutions of the present invention include combinations of drugs, each solution acting on multiple receptors or enzymes.
- the drug agents are thus simultaneously effective against a combination of pathologic processes, including pain and inflammation, and/or processes mediating increases in intraocular pressure.
- the action of these agents is expected to be synergistic, in that the multiple receptor antagonists and inhibitory agonists of the present invention provide a disproportionately increased efficacy in combination relative to the efficacy of the individual agents.
- the solution should result in a clinically significant decrease in operative site pain and inflammation relative to currently used irrigation fluids, thereby decreasing the patient's postoperative analgesic requirement and, where appropriate, allowing earlier patient recovery. It is also expected that preemptively controlling intraocular pressure should decrease the need to treat elevated intraocular procedure post-operatively.
- the present invention provides irrigation solutions for perioperative local application to ocular tissues, including intraocular and topical application, which include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or to decrease or control intraocular pressure, wherein the multiple agents are selected to act on multiple, differing molecular targets to achieve multiple differing physiologic functions.
- the irrigation solutions of the present invention are dilute solutions of multiple pain/inflammation inhibitory agents, IOP reducing agents, and/or mydriatic agents in a physiologic liquid irrigation carrier.
- the carrier is suitably an aqueous solution that may include physiologic electrolytes, such as normal saline or lactated Ringer's solution. More preferably, the carrier includes sufficient electrolytes to provide a physiological balanced salt solution, a cellular energy source, a buffering agent and a free-radical scavenger.
- a solution in accordance with the present invention can include (a) one or more anti-inflammatory agents in combination with one or more analgesic agents, and optionally may also include one or more agents that act to reduce intraocular pressure (“IOP reducing agents”) and/or mydriatic agents; (b) one or more anti-inflammatory agents in combination with one or more IOP reducing agents, and optionally one or more analgesic and/or mydriatic agents; (c) one or more anti-inflammatory agents in combination with one or more mydriatic agents, and optionally one or more analgesic agents and/or IOP reducing agents; (d) one or more analgesic agents in combination with one or more IOP reducing agents, and optionally one or more anti-inflammatory agents and/or mydriatic agents; (e) one or more analgesic agents in combination with one or more mydriatic agents, and optionally one or more anti-inflammatory agents and/or IOP reducing agents; or (f) one or more mydriatic
- any of these solutions of the present invention may also include one or more antibiotic agents.
- Suitable antibiotics for use in the present invention include ciprofloxacin, gentamicin, tobramycin and ofloxacin.
- Other antibiotics that are suitable for perioperative intraocular use are also encompassed by the present invention.
- Suitable concentrations for one antibiotic suitably included in the irrigation solutions of the present invention, ciprofloxacin are 0.01 millimolar to 10 millimolar, preferably 0.05 millimolar to 3 millimolar, most preferably 0.1 millimolar to 1 millimolar. Different antibiotics will be applied at different concentrations, as may be readily determined.
- the agents are included in low concentrations and are delivered locally in low doses relative to concentrations and doses required with conventional methods of drug administration to achieve the desired therapeutic effect. It is impossible to obtain an equivalent therapeutic effect by delivering similarly dosed agents via systemic (e.g., intravenous, subcutaneous, intramuscular or oral) routes of drug administration since drugs given systemically are subject to first- and second-pass metabolism.
- systemic e.g., intravenous, subcutaneous, intramuscular or oral
- each agent may be determined in part based on its dissociation constant, K d .
- the term “dissociation constant” is intended to encompass both the equilibrium dissociation constant for its respective agonist-receptor or antagonist-receptor interaction and the equilibrium inhibitory constant for its respective activator-enzyme or inhibitor-enzyme interaction.
- Each agent is preferably included at a low concentration of 0.1 to 10,000 times K d , except for cyclooxygenase inhibitors, which may be required at larger concentrations depending on the particular inhibitor selected.
- each agent is included at a concentration of 1.0 to 1,000 times K d and most preferably at approximately 100 times K d . These concentrations are adjusted as needed to account for dilution in the absence of metabolic transformation at the local delivery site.
- the exact agents selected for use in the solution, and the concentration of the agents varies in accordance with the particular application.
- the surgical solutions constitute a novel therapeutic approach by combining multiple pharmacologic agents acting at distinct receptor and enzyme molecular targets.
- pharmacologic strategies have focused on the development of highly specific drugs that are selective for individual receptor subtypes and enzyme isoforms that mediate responses to individual signaling neurotransmitters and hormones.
- This standard pharmacologic strategy although well accepted, is not optimal since many other agents simultaneously may be responsible for initiating and maintaining a physiologic effect.
- activation of other receptor subtypes or enzymes and the resultant signal transmission often can trigger a cascade effect. This explains the significant difficulty in employing a single receptor-specific drug to block a pathophysiologic process in which multiple transmitters play a role. Therefore, targeting only a specific individual receptor subtype is likely to be ineffective.
- the therapeutic approach of the present surgical solutions is based on the rationale that a combination of drugs acting simultaneously on distinct molecular targets is required to inhibit the full spectrum of events that underlie the development of a pathophysiologic state.
- the surgical solutions are composed of drugs that target common molecular mechanisms operating in different cellular physiologic processes involved in the development of pain and inflammation, the reduction in intraocular pressure, and the promotion of mydriasis. In this way, the cascading of additional receptors and enzymes in the nociceptive, inflammatory, and intraocular-pressure-increasing pathways is minimized by the surgical solutions.
- the surgical solutions can inhibit the cascade effect both “upstream” and “downstream” (i.e., both at points of divergence and convergence of pathophysiologic pathways).
- Preferred solutions of the present invention for use during ophthalmologic surgical procedures include one or more anti-inflammatory agents in combination with one or more mydriatic agents. Such preferred solutions may also include one or more analgesic agents and/or one or more IOP reducing agents, depending on whether a given procedure or condition treated thereby is associated with a high incidence of pain or increased intraocular procedure, respectively.
- agents are included at dilute concentrations in a physiologic aqueous carrier, such as any of the above-described carriers, e.g., a balanced salt solution.
- the solution may also include a viscosity increasing agent, e.g., a biocompatible and biodegradable polymer, for longer intraocular retention.
- concentrations of the agents are determined in accordance with the teachings of the invention for direct, local application to ocular tissues during a surgical procedure.
- Application of the solution is carried out perioperatively, i.e.: intra-operatively; pre- and intra-operatively; intra- and post-operatively; or pre-, intra- and post-operatively.
- the agents may be provided in a stable one-part or two-part solution, or may be provided in a lyophilized form to which a one-part or two-part carrier liquid is added prior to use.
- Preferred anti-inflammatory agents for use in the ophthalmologic solutions of the present invention include topical steroids, topical non-steroidal anti-inflammatory drugs (NSAIDs) and specific classes of anti-inflammatory agents that are suitably used intraocularly, such as topical anti-histamines, mast cell inhibitors and inhibitors of inducible nitric oxide synthase (iNOS).
- NSAIDs topical non-steroidal anti-inflammatory drugs
- iNOS inducible nitric oxide synthase
- Other anti-inflammatory agents described below as pain/inflammation inhibitory agents, and other anti-inflammatory agents not disclosed herein, which are suitable for ocular use, are also intended to be encompassed by the present invention.
- Examples of steroids that are believed to be suitable for use in the present invention include dexamethasone, fluorometholone and prednisolone.
- Examples of NSAIDS that are believed to be suitable include flurbiprofen, suprofen, diclofenac, ketoprofen and ketorolac. Selection of an NSAID will depend in part on a determination that excessive bleeding will not result.
- Examples of anti-histamines that are believed to be suitable include levocabastine, emedastine and olopatadine.
- Examples of mast cell inhibitors that are believed to be suitable include cromolyn sodium, Iodoxamide and nedocromil.
- agents that act as both anti-histamine agents and mast cell inhibitors include ketotifen and azelastine.
- Inhibitors of iNOS that are believed to be suitable include NG-monomethyl-L-arginine, 1400 W, diphenyleneiodium, S-methyl isothiourea, S-(aminoethyl) isothiourea, L-N 6-(1-iminoethyl)lysine, 1,3-PBITU, and 2-ethyl-2-thiopseudourea.
- analgesic agent as used herein with reference to ophthalmologic solutions and methods is intended to encompass both agents that provide analgesia and agents that provide local anesthesia.
- Preferred analgesic agents for use in the ophthalmologic solutions of the present invention include topical local anesthetics and topical opioids.
- Other analgesic agents described below as pain/inflammation inhibitory agents, and other analgesic agents not disclosed herein, which are suitable for ocular use, are also intended to be encompassed by the present invention.
- Examples of local anesthetics that are believed to be suitable for use in the present invention include lidocaine, tetracaine, bupivacaine and proparacaine.
- Examples of opioids that are believed to be suitable for use in the present invention include morphine, fentanyl and hydromorphone.
- Preferred mydriatic agents for use in the ophthalmologic solutions of the present invention include sympathomimetics, including alpha-1 adrenergic receptor agonists, and anticholinergic agents, including anti-muscarinics.
- Anticholinergic agents may be selected when longer action is desired, because they provide both cycloplegia (paralysis of the ciliary muscle) and mydriasis, e.g., tropicamide exhibits a half-life of approximately 4-6 hours.
- alpha-1 adrenergics will be prefered because they provide mydriasis but not cycloplegia.
- Alpha-1 adrenergics are thus shorter acting, causing mydriasis during a surgical procedure and allowing the pupil to return to its normal state shortly after completion of the procedure.
- suitable adrenergic receptor agonists active at alpha-1 receptors include phenylephrine, epinephrine and oxyrnetazoline.
- suitable anticholinergic agents include tropicamide, cyclopentolate, atropine and homatropine.
- Other agents that cause mydriasis, and particularly short-acting mydriatic agents, are also intended to be encompassed by the present invention.
- Preferred agents that decrease intraocular pressure for use in the ophthalmologic solutions of the present invention include beta adrenergic receptor antagonists, carbonic anhydrase inhibitors, alpha-2 adrenergic receptor agonists and prostaglandin agonists.
- beta adrenergic receptor antagonists are believed to include timolol, metipranolol and levobunolol.
- suitable carbonic anhydrase inhibitors are believed to include brinzolamide and dorzolamide.
- suitable alpha-2 adrenergic receptor agonists are believed to include apraclonidine, brimonidine and oxymetazoline.
- alpha-2 adrenergic receptor agonists suitable for ocular use and described below as inflammatory/pain inhibitory agents may also suitably function as IOP reducing agents within the solutions of the present invention.
- Suitable prostaglandin agonists are believed to include latanoprost, travoprost and bimatoprost.
- an IOP reducing agent other than a prostaglandin agonist may suitably be selected; to avoid the possibility that prostaglandin may enhance post-surgical inflammation.
- Other agents that decrease intraocular pressure are also intended to be encompassed by the present invention.
- agents may be suitable for use in the ophthalmologic solutions and methods of the present invention as analgesic and/or anti-inflammatory agents.
- agent and individual agent(s) within a class, to be utilized for a particular ophthalmologic application can be readily determined by those of skill in the art in accordance with the present invention.
- ocular inflammation models in the rabbit have been studied by comparison of the inflammation response induced by the topical application of several irritating agents, specifically carrageenan, Freund's adjuvant, alkali and croton oil.
- the methods involve measurement of the following parameters which can be determined after the application of each irritant to the eyes of female, white, New Zealand rabbits: comeal edema and the Tyndall effect (slitlamp biomicroscopy), corneal thickness (biometer-pachometer) and aqueous humor levels of the prostaglandin E2 (R.I.A), total protein (Weichselbaum technique), albumin, albumin/globulin (Doumas technique) and leukocytes (coulter counter).
- the above models can be used to test the efficacy of drugs applied topically, such as by irrigation, in inhibiting inflammatory processes and effecting other ocular functions.
- a given agent or combination of agents to be evaluated is applied to the eyes of rabbits after the application of each irritant to the eyes.
- the solution may suitably include agents selected from the following classes of receptor antagonists and agonists and enzyme activators and inhibitors, each class acting through a differing molecular mechanism of action for pain and inflammation inhibition: (1) serotonin receptor antagonists; (2) serotonin receptor agonists; (3) histamine receptor antagonists; (4) bradykinin receptor antagonists; (5) kallikrein inhibitors; (6) tachykinin receptor antagonists, including neurokinin 1 and neurokinin 2 receptor subtype antagonists; (7) calcitonin gene-related peptide (CGRP) receptor antagonists; (8) interleukin receptor antagonists; (9) inhibitors of enzymes active in the synthetic pathway for arachidonic acid metabolites, including (a) phospholipase inhibitors, including PLA 2 isoform inhibitors and PLCY isoform inhibitors, (b) cyclooxygenase inhibitors, and (c) lipooxygenase inhibitors; (10) prostanoid receptor antagonists including eicosa
- Serotonin (5-HT) is thought to produce pain by stimulating serotonin 2 (5-HT 2 ) and/or serotonin 3 (5-HT 3 ) receptors on nociceptive neurons in the periphery.
- 5-HT 3 receptor antagonists by inhibiting nociceptor activation, also may inhibit neurogenic inflammation.
- Activation of 5-HT 2 receptors also may play a role in peripheral pain and neurogenic inflammation.
- One goal of the solution of the present invention is to block pain and a multitude of inflammatory processes.
- 5-HT 2 and 5-HT 3 receptor antagonists may both be suitably used, either individually or together, in the solution of the present invention.
- Amitriptyline (ElavilTM) is believed to be a potentially suitable 5-HT 2 receptor antagonist for use in the present invention.
- Metoclopramide (ReglanTM) is used clinically as an anti-emetic drug, but displays moderate affinity for the 5-HT 3 receptor and can inhibit the actions of 5-HT at this receptor, possibly inhibiting the pain due to 5-HT release from platelets. Thus, it may also be suitable for use in the present invention.
- 5-HT 2 receptor antagonists include imipramine, trazodone, desipramine, ketanserin.
- suitable 5-HT 3 antagonists include cisapride and ondansetron. Therapeutic and preferred concentrations for use of these drugs in the solution of the present invention are set forth in Table 1.
- 5-HT 1A , 5-HT 1B and 5-HT 1D receptors are known to inhibit adenylate cyclase activity.
- serotonin 1A , serotonin 1B and serotonin 1D receptor agonists in the solution should inhibit neurons mediating pain and inflammation.
- serotonin 1E and serotonin 1F receptor agonists because these receptors also inhibit adenylate cyclase.
- Buspirone is a potentially suitable 1 A receptor agonist for use in the present invention.
- Sumatriptan is a potentially suitable 1A, 1B, 1D and 1F receptor agonist.
- a potentially suitable 1 B and 1D receptor agonist is dihydroergotamine.
- a suitable 1E receptor agonist is ergonovine. Therapeutic and preferred concentrations for these receptor agonists are provided in Table 2.
- Histamine receptor antagonists may potentially be included in the irrigation solution.
- Promethazine PhenerganTM
- Other potentially suitable H 1 receptor antagonists include terfenadine, diphenhydramine, amitriptyline, mepyramine and tripolidine. Because amitriptyline is also effective as a serotonin 2 receptor antagonist, it has a dual function as used in the present invention. Suitable therapeutic and preferred concentrations for each of these H 1 receptor antagonists are set forth in Table 3.
- Bradykinin receptors generally are divided into bradykinin 1 (B 1 ) and bradykinin 2 (B 2 ) subtypes. These drugs are peptides (small proteins), and thus they cannot be taken orally, because they would be digested. Antagonists to B 2 receptors block bradykinin-induced acute pain and inflammation. B 1 receptor antagonists inhibit pain in chronic inflammatory conditions. Depending on the application, the solution of the present invention may suitably include either or both bradykinin B 1 and B 2 receptor antagonists.
- bradykinin 1 receptor antagonists for use in the present invention include: the [des-Arg 10 ] derivative of D-Arg-(Hyp 3 -Thi 5 -D-Tic 7 -Oic 8 )-BK (“the [des-Arg 10 ] derivative of HOE 140”, available from Hoechst Pharmaceuticals); and [Leu 8 ] des-Arg 9 -BK.
- bradykinin 2 receptor antagonists include: [D-Phe 7 ]-BK; D-Arg-(Hyp 3 -Thi 5,8 -D-Phe 7 )-BK (“NPC 349”); D-Arg-(Hyp 3 -D-Phe 7 )-BK (“NPC 567”); and D-Arg-(Hyp 3 -Thi 5 -D-Tic 7 -Oic 8 )-BK (“HOE 140”).
- Suitable therapeutic and preferred concentrations are provided in Table 4.
- bradykinin is an important mediator of pain and inflammation. Bradykinin is produced as a cleavage product by the action of kallikrein on high molecular weight kininogens in plasma. Therefore, kallikrein inhibitors are believed to be therapeutic in inhibiting bradykinin production and resultant pain and inflammation.
- a potentially suitable kallikrein inhibitor for use in the present invention is aprotinin. Potentially suitable concentrations for use in the solutions of the present invention are set forth below in Table 5.
- Tachykinins are a family of structurally related peptides that include substance P, neurokinin A (NKA) and neurokinin B (NKB). Neurons are the major source of TKs in the periphery. An important general effect of TKs is neuronal stimulation, but other effects include endothelium-dependent vasodilation, plasma protein extravasation, mast cell recruitment and degranulation and stimulation of inflammatory cells. Due to the above combination of physiological actions mediated by activation of TK receptors, targeting of TK receptors is a reasonable approach for the promotion of analgesia and the treatment of neurogenic inflammation.
- Substance P activates the neurokinin receptor subtype referred to as NKI.
- a potentially suitable Substance P antagonist is ([D-Pro 9 [spiro-gammalactam]Leu 10 ,Trp 11 ]physalaemin-(1-11)) (“GR 82334”).
- Suitable antagonists for use in the present invention which act on the NK 1 receptor are: 1-imino-2-(2-methoxy-phenyl)-ethyl)-7,7-diphenyl-4-perhydroisoindolone(3aR,7aR) (“RP 67580”); and 2S,3S-cis-3-(2-methoxybenzylamino)-2-benzhydrylquinuclidine (“CP 96,345”). Suitable concentrations for these agents are set forth in Table 6.
- Neurokinin A is a peptide which is colocalized in sensory neurons with substance P and which also promotes inflammation and pain. Neurokinin A activates the specific neurokinin receptor referred to as NK 2 .
- NK 2 antagonists include: ((S)-N-methyl-N-[4-(4-acetylamino-4-phenylpiperidino)-2-(3,4-dichlorophenyl)butyl]benzamide (“(O)-SR 48968”); Met-Asp-Trp-Phe-Dap-Leu (“MEN 10,627”); and cyc(Gln-Trp-Phe-Gly-Leu-Met) (“L 659,877”).
- Suitable concentrations of these agents are provided in Table 7. TABLE 7 Therapeutic and Preferred Concentrations of Pain/Inflammation Inhibitory Agents Therapeutic Preferred Concentrations Concentrations Class of Agent (Nanomolar) (Nanomolar) Neurokinin 2 Receptor Subtype Antagonists MEN 10,627 1-1,000 10-1,000 L 659,877 10-10,000 100-10,000 ( ⁇ )-SR 48968 10-10,000 100-10,000
- Calcitonin gene-related peptide is a peptide which is also colocalized in sensory neurons with substance P, and which acts as a vasodilator and potentiates the actions of substance P.
- An example of a potentially suitable CGRP receptor antagonist is I-CGRP-(8-37), a truncated version of CGRP. This polypeptide inhibits the activation of CGRP receptors. Suitable concentrations for this agent are provided in Table 8. TABLE 8 Therapeutic and Preferred Concentrations of Pain/Inflammation Inhibitory Agents Therapeutic Preferred Concentrations Concentrations Class of Agent (Nanomolar) (Nanomolar) CGRP Receptor Antagonist: I-CGRP-(8-37) 1-1,000 10-500
- Interleukins are a family of peptides, classified as cytokines, produced by leukocytes and other cells in response to inflammatory mediators. Interleukins (IL) may be potent hyperalgesic agents peripherally.
- An example of a potentially suitable IL-1 ⁇ receptor antagonist is Lys-D-Pro-Thr, which is a truncated version of IL-1 ⁇ . This tripeptide inhibits the activation of IL-1 ⁇ receptors. Suitable concentrations for this agent are provided in Table 9.
- PLA 2 isoform inhibits the release of arachidonic acid from cell membranes, and therefore inhibits the production of prostaglandins and leukotrienes resulting in decreased inflammation and pain.
- An example of a potentially suitable PLA 2 isoform inhibitor is manoalide. Suitable concentrations for this agent are included in Table 10.
- Inhibition of the phospholipase C (PLC) isoform also will result in decreased production of prostanoids and leukotrienes and, therefore, will result in decreased pain and inflammation.
- PLC isoform inhibitor is 1-[6-((17 ⁇ -3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl]-1H-pyrrole-2,5-dione.
- Nonsteroidal anti-inflammatory drugs are widely used as anti-inflammatory and analgesic agents.
- the molecular targets for these drugs are type I and type II cyclooxygenases (COX-1 and COX-2).
- COX-1 and COX-2 constitutive activity of COX-1 and induced activity of COX-2 both lead to synthesis of prostaglandins that contribute to pain and inflammation.
- NSAIDs currently on the market are generally nonselective inhibitors of both isoforms of COX, but may show greater selectively for COX-1 over COX-2, although this ratio varies for the different compounds.
- Use of COX-1 and COX-2 inhibitors to block formation of prostaglandins represents a better therapeutic strategy than attempting to block interactions of the natural ligands with the seven described subtypes of prostanoid receptors.
- cyclooxygenase inhibitors for use in the present invention are ketoprofen, ketorolac and indomethacin. Therapeutic and preferred concentrations of these agents for use in the solution are provided in Table 11. For some applications, it may also be suitable to utilize a COX-2 specific inhibitor (i.e., selective for COX-2 relative to COX-1) as an anti-inflammatory/analgesic agent.
- COX-2 specific inhibitor i.e., selective for COX-2 relative to COX-1
- Potentially suitable COX-2 inhibitors include rofecoxib (MK 966), SC-58451, celecoxib (SC-58125), meloxicam, nimesulide, diclofenac, NS-398, L-745,337, RS57067, SC-57666 and flosulide.
- lipooxygenase inhibits the production of leukotrienes, such as leukotriene B 4 , which is known to be an important mediator of inflammation and pain.
- leukotriene B 4 an important mediator of inflammation and pain.
- An example of a potentially suitable 5-lipooxygenase antagonist is 2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone (“AA 861”), suitable concentrations for which are listed in Table 12. TABLE 12 Therapeutic and Preferred Concentrations of Pain/Inflammation Inhibitory Agents Therapeutic Preferred Concentrations Concentrations Class of Agent (Nanomolar) (Nanomolar) Lipooxygenase Inhibitor: AA 861 100-10,000 500-5,000
- Specific prostanoids produced as metabolites of arachidonic acid mediate their inflammatory effects through activation of prostanoid receptors.
- classes of specific prostanoid antagonists are the eicosanoid EP-1 and EP-4 receptor subtype antagonists and the thromboxane receptor subtype antagonists.
- a potentially suitable prostaglandin E 2 receptor antagonist is 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-acetylhydrazide (“SC 19220”).
- a potentially suitable thromboxane receptor subtype antagonist is [15-[1 ⁇ , 2 ⁇ (5Z), 3 ⁇ , 4 ⁇ ]-7-[3-[2-(phenylamino)-carbonyl] hydrazino] methyl]-7-oxobicyclo-[2,2,1]-hept-2-yl]-5-heptanoic acid (“SQ 29548”). Suitable concentrations for these agents are set forth in Table 13. TABLE 13 Therapeutic and Preferred Concentrations of Pain/Inflammation Inhibitory Agents Therapeutic Preferred Concentrations Concentrations Class of Agent (Nanomolar) (Nanomolar) Eicosanoid EP-1 Antagonist: SC 19220 100-10,000 500-5,000
- the leukotrienes are products of the 5-lipooxygenase pathway of arachidonic acid metabolism that are generated enzymatically and have important biological properties. Leukotrienes are implicated in a number of pathological conditions including inflammation.
- An example of a potentially suitable leukotriene B 4 receptor antagonist is SC (+)-(S)-7-(3-(2-(cyclopropylmethyl)-3-methoxy-4-[(methylamino)-carbonyl]phenoxy(propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-propanoic acid (“SC 53228”).
- Opioid receptors include the ⁇ -, ⁇ - and ⁇ -opioid receptor subtypes.
- Examples of potentially suitable ⁇ -opioid receptor agonists are fentanyl and Try-D-Ala-Gly-[N-MePhe]-NH(CH 2 )—OH (“DAMGO”).
- An example of a potentially suitable 6-opioid receptor agonist is [D-Pen 2 ,D-Pen 5 ]enkephalin (“DPDPE”).
- K-opioid receptor agonist is (trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidnyl)cyclohexyl]-benzene acetamide (“U50,488”). Suitable concentrations for each of these agents are set forth in Table 15.
- Extracellular ATP acts as a signaling molecule through interactions with P 2 purinoceptors.
- P 2X purinoceptors are the P 2X purinoceptors which are ligand-gated ion channels possessing intrinsic ion channels permeable to Na + , K + , and Ca 2+ .
- Potentially suitable antagonists of P 2X /ATP purinoceptors for use in the present invention include, by way of example, suramin and pyridoxylphosphate-6-azophenyl-2,4-disulfonic acid (“PPADS”). Suitable concentrations for these agents are provided in Table 16.
- Agonists of the P 2Y receptor are known to effect smooth muscle relaxation through elevation of inositol triphosphate (IP 3 ) levels with a subsequent increase in intracellular calcium.
- IP 3 inositol triphosphate
- An example of a P 2Y receptor agonist is 2-me-S-ATP.
- K + channel openers for the practice of the present invention include: ( ⁇ )pinacidil; cromakalim; nicorandil; minoxidil; N-cyano-N′-[1,1-dimethyl-[ 2,2,3,3- 3 H]propyl]-N′′-(3-pyridinyl)guanidine (“P 1075”); and N-cyano-N′-(2-nitroxyethyl)-3-pyridinecarboximidamide monomethansulphonate (“KRN 2391”). Concentrations for these agents are set forth in Table 17.
- the solution of the present invention is preferably used for continuous infusion throughout the surgical procedure to provide preemptive inhibition of pain and inflammation.
- Local anesthetics e.g., lidocaine, bupivacaine, etc.
- lidocaine e.g., bupivacaine, etc.
- analgesic agents e.g., bupivacaine, etc.
- lidocaine a local anesthetic
- nerve injury discharge Bosset K and Tanalian DL, Concentration-dependent Effects of Lidocaine on Corneal Epithelial Wound Healing, Invest Ophthalmol Vis Sci 33(11), pp. 3029-3033, 1992. Therefore, in addition to decreasing pain signals, local anesthetics, when delivered in extremely low concentrations, also have anti-inflammatory properties.
- a local anesthetic in extremely low or “sub-anesthetic” concentrations in the irrigation solution provides a beneficial anti-inflammatory effect without exposing the patient to the systemic toxicity associated with currently used clinical doses of local anesthetics.
- a local anesthetic is suitable for use in the present invention.
- Examples of representative local anesthetics useful in the practice of the present invention include, without limitation, benzocaine, bupivacaine, chloroprocaine, cocaine, etiodocaine, lidocaine, mepivacaine, pramoxine, prilocalne, procaine, proparacaine, ropivacaine, tetracaine, dibucaine, QX-222, ZX-314, RAC-109, HS-37 and the pharmacologically active enantiomers thereof.
- some local anesthetics are believed to act by inhibiting voltage-gated sodium channels. (See Guo, X.
- useful concentratons of anesthetic agents delivered locally are generally in the range of about 125 to about 100,000,000 nanomolar, more preferably about 1,000 to about 10,000,000 nanomolar, and most preferably about 225,000 to about 1,000,000 nanomolar.
- the solutions of the invention comprise at least one local anesthetic agent delivered locally at a concentration of no greater than 750,000 nanomolar.
- the solutions of the invention comprise at least one local anesthetic agent delivered locally at a concentration of no greater than 500,000 nanomolar.
- Useful concentrations of representative specific local anesthetic agents are set forth below. TABLE 18 Therapeutic and Preferred Concentrations of Specific Local Anesthetic Agents Local Concentrations (Nanomolar) Anesthetics: Therapeutic Preferred More Preferred lidocaine 500-1,600,000 4,000-1,200,000 900,000-1,100,000 bupivacaine 125-400,000 1,000-300,000 225,000-275,000
- All the individual nine receptors that comprise the adrenergic amine receptor family belong to the G-protein linked superfamily of receptors.
- the classification of the adrenergic family into three distinct subfamilies, namely ⁇ 1 (alpha-1), ⁇ 2 (alpha-2), and ⁇ (beta), is based upon a wealth of binding, functional and second messenger studies.
- Each adrenergic receptor subfamily is itself composed of three homologous receptor subtypes that have been defined by cloning and pharmacological characterization of the recombinant receptors.
- amino acid identities in the membrane spanning domain range from 36-73%. However, between members of the same subfamily ( ⁇ 1A vs. ⁇ 1B ) the identity between membrane domains is usually 70-80%. Together, these distinct receptor subtypes mediate the effects of two physiological agonists, epinephrine and norepinephrine.
- Distinct adrenergic receptor types couple to unique sets of G-proteins and are thereby capable of activating different signal transduction effectors.
- the classification of alpha-1, alpha-2, and beta subfamilies not only defines the receptors with regard to signal transduction mechanisms, but also accounts for their ability to differentially recognize various natural and synthetic adrenergic amines.
- a number of selective ligands have been developed and utilized to characterize the pharmacological properties of each of these receptor types.
- alpha-i receptors Functional responses of alpha-i receptors have been shown in certain systems to stimulate phosphatidylinositol turnover and promote the release of intracellular calcium (via G q ), while stimulation of alpha-2 receptors inhibits adenylyl cyclase (via G i ). In contrast, functional responses of beta receptors are coupled to increases in adenylyl cyclase activity and increases in intracellular calcium (via G i ).
- alpha-I receptor subtypes which all exhibit a high affinity (subnanomolar) for the antagonist, prazosin.
- the subdivision of alpha-i adrenoceptors into three different subtypes, designated ⁇ 1A , ⁇ 1B , and ⁇ 1D has been primarily based on extensive ligand binding studies of endogenous receptors and cloned receptors. Pharmacological characterization of the cloned receptors led to revisions of the original classification such that the clone originally called the ⁇ 1C subtype corresponds to the pharmacologically defined ⁇ 1A receptor. Agonist occupation of ⁇ 1A-D receptor subtypes results in activation of phospholipase C, stimulation of PI breakdown, generation of the IP 3 as second messenger and an increase in intracellular calcium.
- ⁇ 2A Three different ⁇ 2 -receptor subtypes have been cloned, sequenced, and expressed in mammalian cells, referred to as ⁇ 2A ( ⁇ 2 C10), ⁇ 2B ( ⁇ 2- C2), ⁇ 2C ( ⁇ 2- C4). These subtypes not only differ in their amino acid composition but also in their pharmacological profiles and distributions.
- ⁇ 2D gene rg20
- the signal transduction pathways are similar for all three ⁇ 2A receptor subtypes; each is negatively coupled to adenylate cyclase via G i/o .
- the ⁇ 2A and ⁇ 2B receptors have also been reported to mediate activation of a G-protein coupled potassium channel (receptor-operated) as well as inhibition of a G-protein associated calcium channel.
- Agonists selective for the alpha-2 adrenergic receptor class relative to the alpha-1 adrenergic receptor class are UK14,304, BHT920 and BHT933.
- alpha-2 adrenergic receptor ligands which are imidazolines (clonidine, idazoxan) and others (oxymetazoline and UK14304) also bind with high affinity (nanomolar) to non-adrenoceptor imidazoline binding sites.
- species variation in the pharmacology of the ⁇ 2A -adrenoceptor exists.
- subtype-selective alpha-2 adrenergic receptor ligands show only minimal selectivity or are nonselective with respect to other specific receptors, such that the therapeutic properties of subtype selective drugs are still under development.
- alpha-2 receptor agonists may be considered to have potential use is as an adjunct to anesthesia, for the control of pain and blockade of neurogenic inflammation.
- Sympathetic nervous system stimulation releases norepinephrine after tissue injury, and thus influences nociceptor activity.
- Alpha-2 receptor agonists such as clonidine, can inhibit norepinephrine release at terminal nerve fibre endings and thus may induce analgesia directly at peripheral sites (without actions on the CNS).
- the ability of primary afferent neurons to release neurotransmitters from both their central and peripheral endings enables them to exert a dual, sensory and “efferent” or “local effector” function.
- neurogenic inflammation is used to describe theefferent function of the sensory nerves that includes the release of sensory neuropeptides that contribute, in a “feed-forward” manner, to the inflammatory process.
- Drugs that block release of neuropeptides (substance P, CGRP) from sensory endings are predicted to possess analgesic and anti-inflammatory activity.
- Clonidine is considered to exhibit nonopiate anti-nociceptive properties, which might allow its use as an alternative for postoperative analgesia.
- clonidine was found to delay the onset of pain and decrease the pain score.
- alpha-2 receptor agonists such as UK14304
- these compounds are expected to exhibit anti-nociceptive action on the peripheral terminals of primary afferent nerves when applied intraoperatively in an irrigation solution directly to tissues.
- Alpha-2 receptor agonists are suitable for use in the current invention, delivered either as a single agent or in combination with other anti-pain and/or anti-inflammatory drugs, to inhibit pain and inflammation.
- Representative alpha-2 receptor agonists for the practice of the present invention include, for example: clonidine; dexmedetomidine; oxymetazoline; ((R)-( ⁇ )-3′-(2-amino-1-hydroxyethyl)-4′-fluoro-methanesulfoanilide (NS-49); 2-[(5-methylbenz-1- ⁇ -4-azin-6-yl)imino]imidazoline (AGN-193080); AGN 191103 and AGN 192172, as described in Munk, S.
- selection of preferred agents to include in an ophthalmologic irrigation solution takes into consideration particular agents that display efficacy in more than one of the above functional classes.
- the previously described alpha-2 adrenergic receptor agonists provide examples of this, as they may function as both IOP reducing agents and agents that inhibit inflammation and pain.
- oxymetazoline inhibits ocular inflammation by inhibiting release of sensory neurotransmitters (Fuder H., J Ocul. Pharmacol., 10:109-123 (1994)).
- Oxymetazoline also functions as a mydriatic agent via agonist activity at alpha-1-adrenergic receptors and also decreases IOP via agonist activity at alpha-2-adrenergic receptors (Chu T. et al, Pharmacology, 53:259-270 (1996)).
- NSAIDS in addition to anti-inflammatory effects, also are indicated for inhibiting intra-operative miosis, thereby possessing mydriatic properties.
- Such multi-functional agents may suitably be used in the ophthalmologic solutions of the present invention when combined with an additional agent or agents that provide at least one additional ophthalmologic function not already provided by the multi-functional agent.
- NSAIDS have been demonstrated to be as effective as steroids for controlling inflammation following ocular surgery (Dadeya S. et al, J. Pediatr. Ophthalmol. Strabismus., 39:166-168 (2002)), NSAIDS are preferred to avoid the potential non-specific detrimental effects of steroids.
- irrigation solutions of the present invention including 2 or more agents may be formulated in accordance with the present invention, but each solution might not include agents drawn from all of the named functional categories (i.e., analgesic, anti-inflammatory, mydriati, and IOP reducing agents).
- agents drawn from all of the named functional categories i.e., analgesic, anti-inflammatory, mydriati, and IOP reducing agents.
- an irrigation solution formulated in accordance with the disclosure herein for use during cataract surgery may not require an analgesic, because this procedure is not as painful as a vitrectomy.
- the active agents of the present invention are solubilized within a physiologic liquid irrigation carrier.
- the carrier is suitably an aqueous solution that may include physiologic electrolytes, such as normal saline or lactated Ringer's solution. More preferably, the carrier includes one or more adjuvants, and preferably all of the following adjuvants: sufficient electrolytes to provide a physiological balanced salt solution; a cellular energy source; a buffering agent; and a free-radical scavenger.
- One suitable solution includes: electrolytes of from 50 to 500 millimolar sodium ions, from 0.1 to 50 millimolar potassium ions, from 0.1 to 5 millimolar calcium ions, from 0.1 to 5 millimolar magnesium ions, from 50 to 500 millimolar chloride ions, and from 0.1 to 10 millimolar phosphate; bicarbonate as a buffer at a concentration of from 10 to 50 millimolar; a cellular energy source selected from dextrose and glucose, at a concentration of from 1 to 25 millimolar; and glutathione as a free-radical scavenger (i.e., anti-oxidant) at a concentration of from 0.05 to 5 millimolar.
- the pH of the irrigation solution is suitable when controlled at between 5.5 and 8.0, preferably at a pH of 7.4.
- the solution of the present invention has applications for a variety of operative/interventional procedures, including surgical, diagnostic and therapeutic techniques.
- the irrigation solution is applied perioperatively during ophthalmologic surgery.
- the term “perioperative” encompasses application intraprocedurally, pre- and intraprocedurally, intra- and postprocedurally, and pre-, intra- and postprocedurally.
- the solution is applied preprocedurally and/or postprocedurally as well as intraprocedurally.
- the irrigation solution is most preferably applied to the wound or surgical site prior to the initiation of the procedure, preferably before substantial tissue trauma, and continuously throughout a major portion or for the duration of the procedure, to preemptively block pain and inflammation, inhibit intraocular pressure increases, and/or cause mydriasis.
- continuous application of the irrigation fluid of the present invention may be carried out as an uninterrupted application, or repeated and frequent irrigation of wounds or procedural sites at a frequency sufficient to maintain a predetermined therapeutic local concentration of the applied agents, or an application in which there may be intermittent cessation of irrigation fluid flow necessitated by operating technique.
- additional amounts of the therapeutic agents may be introduced, such as by intraocular injection of an additional amount of the irrigation fluid including the same or a higher concentration of the active agents, or by intraocular injection or topical application of the agents in a viscoelastic gel.
- concentrations listed for each of the agents within the solutions of the present invention are the concentrations of the agents delivered locally, in the absence of metabolic transformation, to the operative site in order to achieve a predetermined level of effect at the operative site.
- This solution utilizes extremely low doses of these pain and inflammation inhibitors, due to the local application of the agents directly to the operative site during the procedure.
- the agents are included in low concentrations and are delivered locally in low doses relative to concentrations and doses required with systemic methods of drug administration to achieve the desired therapeutic effect at the procedural site.
- Exemplary ophthalmologic solutions of the present invention for use during cataract removal surgery are described in Tables 20, 21 and 22. This solution, and the following solutions of Tables 23-25, are provided by way of example only, and are not intended to limit the invention.
- Anti-inflammatories are believed to be particularly useful in cataract solutions of the invention, to potentially reduce the post-operative incidence of, or hasten resolution of, cystoid macular edema (CME).
- CME cystoid macular edema
- These exemplary solutions and the other exemplary ophthalmologic irrigation solutions described herein below are provided in terms of the concentration of each agent included in the previously described preferred balanced-salt solution.
- the solution may suitably be supplied in 500 ml bags, this being the quantity of irrigation solution typically applied during a procedure, by way of non-limiting example.
- Irrigation solutions suitably used for extensive ophthalmologic surgery or posterior ocular chamber procedures, such as vitrectomy, provide increased analgesia by the addition of a local anesthetic.
- solutions of the present invention including a local anesthetic are provided in Tables 24 and 25.
- timolol 10-1,000,000 100-100,000 1,000-10,000 agent anti- flurbi- 10-1,000,000 100-100,000 1,000-10,000 inflam- profen matory mydriatic tropica- 10-1,000,000 100-100,000 1,000-10,000 mide analgesic lidocaine 1,000- 10,000- 100,000- 100,000,000 10,000,000 1,000,000
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/630,626 US20040072809A1 (en) | 2002-07-30 | 2003-07-30 | Ophthalmologic irrigation solutions and method |
US12/799,981 US8173707B2 (en) | 2002-07-30 | 2010-05-05 | Ophthalmologic irrigation solutions and method |
US13/420,440 US20130079344A1 (en) | 2002-07-30 | 2012-03-14 | Ophthalmologic irrigation solutions and method |
US13/420,456 US8586633B2 (en) | 2002-07-30 | 2012-03-14 | Ophthalmologic irrigation solutions and method |
US14/075,588 US9399040B2 (en) | 2002-07-30 | 2013-11-08 | Ophthalmologic irrigation solutions and method |
US14/186,146 US9278101B2 (en) | 2002-07-30 | 2014-02-21 | Ophthalmologic irrigation solutions and method |
US14/946,435 US9585895B2 (en) | 2002-07-30 | 2015-11-19 | Ophthalmologic irrigation solutions and method |
US15/198,208 US20170100412A1 (en) | 2002-07-30 | 2016-06-30 | Ophthalmologic irrigation solutions and method |
US15/414,930 US20170312295A1 (en) | 2002-07-30 | 2017-01-25 | Ophthalmologic Irrigation Solutions and Method |
US17/551,969 US20220175797A1 (en) | 2002-07-30 | 2021-12-15 | Ophthalmologic irrigation solutions and method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39989902P | 2002-07-30 | 2002-07-30 | |
US10/630,626 US20040072809A1 (en) | 2002-07-30 | 2003-07-30 | Ophthalmologic irrigation solutions and method |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/799,981 Continuation US8173707B2 (en) | 2002-07-30 | 2010-05-05 | Ophthalmologic irrigation solutions and method |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040072809A1 true US20040072809A1 (en) | 2004-04-15 |
Family
ID=31188639
Family Applications (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/630,626 Abandoned US20040072809A1 (en) | 2002-07-30 | 2003-07-30 | Ophthalmologic irrigation solutions and method |
US12/799,981 Expired - Lifetime US8173707B2 (en) | 2002-07-30 | 2010-05-05 | Ophthalmologic irrigation solutions and method |
US13/420,440 Abandoned US20130079344A1 (en) | 2002-07-30 | 2012-03-14 | Ophthalmologic irrigation solutions and method |
US13/420,456 Expired - Lifetime US8586633B2 (en) | 2002-07-30 | 2012-03-14 | Ophthalmologic irrigation solutions and method |
US14/075,588 Expired - Lifetime US9399040B2 (en) | 2002-07-30 | 2013-11-08 | Ophthalmologic irrigation solutions and method |
US14/186,146 Expired - Fee Related US9278101B2 (en) | 2002-07-30 | 2014-02-21 | Ophthalmologic irrigation solutions and method |
US14/946,435 Expired - Lifetime US9585895B2 (en) | 2002-07-30 | 2015-11-19 | Ophthalmologic irrigation solutions and method |
US15/198,208 Abandoned US20170100412A1 (en) | 2002-07-30 | 2016-06-30 | Ophthalmologic irrigation solutions and method |
US15/414,930 Abandoned US20170312295A1 (en) | 2002-07-30 | 2017-01-25 | Ophthalmologic Irrigation Solutions and Method |
US17/551,969 Abandoned US20220175797A1 (en) | 2002-07-30 | 2021-12-15 | Ophthalmologic irrigation solutions and method |
Family Applications After (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/799,981 Expired - Lifetime US8173707B2 (en) | 2002-07-30 | 2010-05-05 | Ophthalmologic irrigation solutions and method |
US13/420,440 Abandoned US20130079344A1 (en) | 2002-07-30 | 2012-03-14 | Ophthalmologic irrigation solutions and method |
US13/420,456 Expired - Lifetime US8586633B2 (en) | 2002-07-30 | 2012-03-14 | Ophthalmologic irrigation solutions and method |
US14/075,588 Expired - Lifetime US9399040B2 (en) | 2002-07-30 | 2013-11-08 | Ophthalmologic irrigation solutions and method |
US14/186,146 Expired - Fee Related US9278101B2 (en) | 2002-07-30 | 2014-02-21 | Ophthalmologic irrigation solutions and method |
US14/946,435 Expired - Lifetime US9585895B2 (en) | 2002-07-30 | 2015-11-19 | Ophthalmologic irrigation solutions and method |
US15/198,208 Abandoned US20170100412A1 (en) | 2002-07-30 | 2016-06-30 | Ophthalmologic irrigation solutions and method |
US15/414,930 Abandoned US20170312295A1 (en) | 2002-07-30 | 2017-01-25 | Ophthalmologic Irrigation Solutions and Method |
US17/551,969 Abandoned US20220175797A1 (en) | 2002-07-30 | 2021-12-15 | Ophthalmologic irrigation solutions and method |
Country Status (18)
Country | Link |
---|---|
US (10) | US20040072809A1 (sl) |
EP (1) | EP1534313B1 (sl) |
JP (11) | JP2006504661A (sl) |
CN (3) | CN103143022A (sl) |
AU (2) | AU2003261304A1 (sl) |
BE (1) | BE2015C078I2 (sl) |
CA (2) | CA2493581C (sl) |
CY (1) | CY2015055I1 (sl) |
DK (1) | DK1534313T3 (sl) |
ES (1) | ES2397574T3 (sl) |
FR (1) | FR15C0090I2 (sl) |
HK (1) | HK1081455A1 (sl) |
HU (1) | HUS1500069I1 (sl) |
LU (1) | LU92923I2 (sl) |
NL (1) | NL300784I2 (sl) |
PT (1) | PT1534313E (sl) |
SI (1) | SI1534313T1 (sl) |
WO (1) | WO2004010894A2 (sl) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060183698A1 (en) * | 2004-06-07 | 2006-08-17 | Ista Pharmaceuticals, Inc. | Ophthalmic formulations and uses thereof |
WO2007117996A2 (en) | 2006-04-03 | 2007-10-18 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
US20080153818A1 (en) * | 2006-12-21 | 2008-06-26 | Bingaman David P | Methods for preventing inflammation during surgery |
US20080194649A1 (en) * | 2005-03-09 | 2008-08-14 | Laboratoires Thea | Ophthalmologic Compositions And Use Mode Thereof |
WO2008151288A2 (en) * | 2007-06-05 | 2008-12-11 | Xenon Pharmaceuticals Inc. | Aromatic and heteroaromatic compounds useful in treating iron disorders |
US20100069482A1 (en) * | 2006-12-22 | 2010-03-18 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of ophthalmic drugs |
WO2010053487A1 (en) * | 2008-11-07 | 2010-05-14 | Cydex Pharmaceuticals, Inc. | Composition containing sulfoalkyl ether cyclodextrin and latanoprost |
US20100240624A1 (en) * | 2009-03-17 | 2010-09-23 | Aciex Therapeutics, Inc. | Ophthalmic Formulations of Ketotifen and Methods of Use |
US20110028516A1 (en) * | 2005-08-26 | 2011-02-03 | Fu-Pao Tsao | Stabilized and preserved ketoifen ophthalmic compositions |
EP2382991A1 (en) | 2004-06-10 | 2011-11-02 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
WO2012139081A2 (en) | 2011-04-08 | 2012-10-11 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
US8748402B2 (en) | 2004-06-07 | 2014-06-10 | Bausch & Lomb Pharma Holdings Corp. | Ophthalmic formulations and uses thereof |
US20140162990A1 (en) * | 2012-12-06 | 2014-06-12 | Alcon Research, Ltd. | Finafloxacin suspension compositions |
US20140235691A1 (en) * | 2012-10-24 | 2014-08-21 | Omeros Corporation | Stable Preservative-free Mydriatic and Anti-inflammatory Solutions for Injection |
USD750768S1 (en) | 2014-06-06 | 2016-03-01 | Anutra Medical, Inc. | Fluid administration syringe |
US9278101B2 (en) | 2002-07-30 | 2016-03-08 | Omeros Corporation | Ophthalmologic irrigation solutions and method |
US9387151B2 (en) | 2013-08-20 | 2016-07-12 | Anutra Medical, Inc. | Syringe fill system and method |
USD763433S1 (en) | 2014-06-06 | 2016-08-09 | Anutra Medical, Inc. | Delivery system cassette |
USD774182S1 (en) | 2014-06-06 | 2016-12-13 | Anutra Medical, Inc. | Anesthetic delivery device |
EP3150635A2 (en) | 2009-10-16 | 2017-04-05 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US10220012B2 (en) * | 2016-06-03 | 2019-03-05 | Joerg H. KRUMEICH | Solution for ophthalmology |
US11045432B2 (en) | 2013-10-03 | 2021-06-29 | Harrow Ip, Llc | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof |
US11071724B2 (en) | 2019-05-17 | 2021-07-27 | Ocular Science, Inc. | Compositions and methods for treating presbyopia |
US11234965B2 (en) | 2014-12-01 | 2022-02-01 | Omeros Corporation | Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions |
US11390654B2 (en) * | 2016-09-02 | 2022-07-19 | Christopher Joseph Soares | Use of CGRP receptor antagonists in neuroprotection and neurological disorders |
US11395825B2 (en) | 2017-05-04 | 2022-07-26 | Ocular Science, Inc. | Compositions and methods for treating eyes and methods of preparation |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006018997A1 (ja) * | 2004-08-18 | 2006-02-23 | Medrx Co., Ltd. | 外用剤 |
CN101347620B (zh) * | 2007-07-20 | 2012-04-25 | 天津药业研究院有限公司 | 一种药物组合物及其在制备治疗青光眼的药物中的应用 |
WO2010050211A1 (ja) | 2008-10-30 | 2010-05-06 | 国立大学法人 岡山大学 | 局所麻酔用組成物 |
GB0915319D0 (en) * | 2009-09-03 | 2009-10-07 | Sharma Anant | Combination medicament |
WO2012111029A2 (en) * | 2011-02-18 | 2012-08-23 | M/S. Appasamy Associates | Ophthalmic composition for enabling dilation of pupils |
ITPA20110004A1 (it) * | 2011-02-23 | 2012-08-24 | Francesco Paolo Montalto | Iniezione intracamerulare per anestesia e dilatazione pupillare (midriasi). |
RU2525512C1 (ru) * | 2013-03-28 | 2014-08-20 | федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ медикаментозного расширения ригидного зрачка перед проведением факоэмульсификации |
KR20160004288A (ko) | 2013-05-06 | 2016-01-12 | 가오슝 창 궁 메모리얼 하스피털 | 약학적 조성물 및 이의 용도 |
RU2529787C1 (ru) * | 2013-06-03 | 2014-09-27 | федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Офтальмологический ирригационный раствор |
WO2015117024A1 (en) | 2014-01-31 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Novel therapeutics for the treatment of glaucoma |
CN104324049A (zh) * | 2014-09-26 | 2015-02-04 | 浙江天瑞药业有限公司 | 一种制备关节手术用平衡盐冲洗液的方法 |
CN104856990A (zh) * | 2015-05-07 | 2015-08-26 | 武汉武药科技有限公司 | 去氧肾上腺素酮咯酸溶液及制备方法 |
CN105213418B (zh) * | 2015-11-11 | 2019-01-22 | 中国人民解放军第四军医大学 | 一种眼科术前用复方滴眼液及其制备方法 |
US10231968B2 (en) | 2016-08-01 | 2019-03-19 | David R. Hardten | Medicinal solution to be continuously or pulse-delivered to the eye for treating ophthalmological conditions/maladies |
EP3503873A4 (en) | 2016-08-25 | 2020-04-15 | Harrow IP, LLC | EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHOD FOR THE PRODUCTION THEREOF |
CN107137713A (zh) * | 2017-05-12 | 2017-09-08 | 浙江工贸职业技术学院 | 一种眼科手术后用冲洗液及其制备方法 |
US20180353504A1 (en) * | 2017-06-08 | 2018-12-13 | Eye Therapies, Llc | Low-dose brimonidine combinations and uses thereof |
EP3706868A4 (en) * | 2017-11-10 | 2021-12-15 | The Regents of the University of Colorado, a Body Corporate | METHOD OF INDUCING PUPIL DILATATION |
LT3681500T (lt) | 2018-04-24 | 2022-06-27 | Allergan, Inc. | Pilokarpino hidrochlorido naudojimas presbiopijos gydymui |
WO2020184566A1 (ja) | 2019-03-11 | 2020-09-17 | 日本放送協会 | 画像符号化装置、画像復号装置、及びプログラム |
WO2021158992A1 (en) * | 2020-02-07 | 2021-08-12 | Qlaris Bio, Inc. | Improved methods and compositions for cromakalim prodrug therapy |
US11883382B2 (en) | 2021-07-23 | 2024-01-30 | Somerset Therapeutics, Llc | Buffer-free ophthalmological compositions of ketorolac and phenylephrine and applications thereof |
WO2023048174A1 (ja) * | 2021-09-22 | 2023-03-30 | テイカ製薬株式会社 | 角膜疾患治療剤 |
Citations (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4474811A (en) * | 1981-12-24 | 1984-10-02 | Kakenyaku Kako Co., Ltd. | Anti-inflammatory ophthalmic solution and process for preparing the same |
US4474751A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
US4550022A (en) * | 1981-10-05 | 1985-10-29 | Alcon Laboratories, Inc. | Tissue irrigating solution |
US4876250A (en) * | 1988-10-31 | 1989-10-24 | Alcon Laboratories, Inc. | Methods for controlling ocular hypertension with angiostatic steroids |
US4938970A (en) * | 1987-02-06 | 1990-07-03 | Hustead Robert E | Painless electrolyte solutions |
US5110493A (en) * | 1987-09-11 | 1992-05-05 | Syntex (U.S.A.) Inc. | Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant |
US5212196A (en) * | 1986-10-21 | 1993-05-18 | Alcon Laboratories, Inc. | Control of post-surgical intraocular pressure using clonidine derivatives |
US5298487A (en) * | 1989-05-03 | 1994-03-29 | The Johns Hopkins University | Effective ophthalmic irrigation solution |
US5371078A (en) * | 1988-10-31 | 1994-12-06 | Alcon Laboratories, Inc. | Angiostatic steroids and methods and compositions for controlling ocular hypertension |
US5523316A (en) * | 1994-06-23 | 1996-06-04 | Alcon Laboratories, Inc. | Intraocular irrigating solution containing agent for controlling IOP |
US5587175A (en) * | 1991-10-30 | 1996-12-24 | Mdv Technologies, Inc. | Medical uses of in situ formed gels |
US5612027A (en) * | 1995-04-18 | 1997-03-18 | Galin; Miles A. | Controlled release of miotic and mydriatic drugs in the anterior chamber |
US5624893A (en) * | 1993-10-14 | 1997-04-29 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation |
US5696091A (en) * | 1993-09-29 | 1997-12-09 | Alcon Laboratories, Inc. | Use of growth factor and antimetabolite combination to prevent or retard secondary cataract formation |
US5767105A (en) * | 1995-05-03 | 1998-06-16 | Peyman; Gholam A. | Ocular solution |
US5798356A (en) * | 1995-08-07 | 1998-08-25 | Alcon Laboratories, Inc. | Angiostatic compounds |
US5800385A (en) * | 1994-12-12 | 1998-09-01 | Omeros Medical Systems, Inc. | Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis |
US5811446A (en) * | 1997-04-18 | 1998-09-22 | Cytos Pharmaceuticals Llc | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor |
US5820583A (en) * | 1995-12-12 | 1998-10-13 | Omeros Medical Systems, Inc. | Surgical irrigation solution and method for inhibition of pain and inflammation |
US5972326A (en) * | 1995-04-18 | 1999-10-26 | Galin; Miles A. | Controlled release of pharmaceuticals in the anterior chamber of the eye |
US6030974A (en) * | 1997-04-02 | 2000-02-29 | The Regents Of The University Of California | Method of anesthesia |
US6117907A (en) * | 1993-04-14 | 2000-09-12 | Sher; Neal A. | Topical treatment of ocular pain after corneal surgery |
US6218428B1 (en) * | 2000-04-28 | 2001-04-17 | Emil Chynn | Ophthalmic composition |
US6280745B1 (en) * | 1997-12-23 | 2001-08-28 | Alliance Pharmaceutical Corp. | Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions |
US6395746B1 (en) * | 1998-09-30 | 2002-05-28 | Alcon Manufacturing, Ltd. | Methods of treating ophthalmic, otic and nasal infections and attendant inflammation |
US20020071874A1 (en) * | 2000-07-14 | 2002-06-13 | Allergan Sales, Inc. | Compositions containing therapeutically active components having enhanced solubility |
US6413961B1 (en) * | 1995-12-12 | 2002-07-02 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain and inflammation |
US20020128267A1 (en) * | 2000-07-13 | 2002-09-12 | Rebanta Bandyopadhyay | Method of using COX-2 inhibitors in the treatment and prevention of ocular COX-2 mediated disorders |
US20020183279A1 (en) * | 2001-04-18 | 2002-12-05 | Koichiro Tanaka | Pharmaceutical composition containing viscoelastic substance and medication |
US6492332B1 (en) * | 1995-12-12 | 2002-12-10 | Omeros Corporation | Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation |
US6495598B1 (en) * | 1997-04-22 | 2002-12-17 | Ophtecs Corporation | Perfusate preparation for ophthalmic operation |
US20030017199A1 (en) * | 2001-05-03 | 2003-01-23 | Woodward David F. | Compositions having enhanced pharmacokinetic characteristics |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987007141A1 (en) | 1986-05-23 | 1987-12-03 | New England Medical Center Hospitals, Inc. | Method for treating glaucoma |
US5036046A (en) | 1988-10-12 | 1991-07-30 | Eye Research Institute Of Retina Foundation, Inc. | Method for enhancing healing of corneal endothelial wounds |
US5051443A (en) | 1988-10-12 | 1991-09-24 | Eye Research Institute Of Retina Foundation, Inc. | Method for enhancing healing of corneal endothelial wounds |
JPH05502217A (ja) | 1989-08-21 | 1993-04-22 | ベス イスラエル ホスピタル アソシエーション | セロトニン拮抗薬の局所用調製物を使用した、皮膚、眼、および粘膜の過敏症、炎症、および過増殖状態の治療のための方法および組成物 |
EP0502143B1 (en) | 1990-09-07 | 1995-11-08 | Universidad De Alicante | Composition for treating ocular pain |
IT1252692B (it) * | 1991-11-27 | 1995-06-23 | Zambon Spa | Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi |
CA2126093A1 (en) * | 1992-10-21 | 1994-04-28 | Owen Gan | Composition for irrigating intraocular tissues and maintaining mydriasis during intraocular surgery |
CA2149528A1 (en) | 1993-09-29 | 1995-04-06 | Billie M. York | Compositions containing growth factors and antimetabolites |
JPH09506620A (ja) | 1993-12-17 | 1997-06-30 | アルコン・ラボラトリーズ,インコーポレイテッド | 非ステロイド抗炎症剤を含有する改良された眼内洗浄溶液 |
US6350781B1 (en) * | 1994-01-14 | 2002-02-26 | Lee Shahinia, Jr. | Method and analgesic preparations for sustained and extended corneal analgesia with subanesthetic concentrations of lidocaine |
WO1995034298A1 (en) | 1994-06-10 | 1995-12-21 | Telor Ophthalmic Pharmaceuticals, Inc. | Inhibition of intraoperative miosis/production of mydriasis by local anesthetics |
WO2000023062A2 (en) | 1998-10-20 | 2000-04-27 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain and inflammation |
US7091181B2 (en) | 1994-12-12 | 2006-08-15 | Omeros Corporation | Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors |
WO2000023066A2 (en) | 1998-10-20 | 2000-04-27 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain and inflammation |
KR100517210B1 (ko) | 1994-12-12 | 2006-06-07 | 오메로스 코포레이션 | 통증,염증및경련억제용관주용액 |
US5849761A (en) | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
WO1998004171A1 (en) | 1996-07-26 | 1998-02-05 | Schein Dental Equipment Co. | Armrest mechanism for dental chairs |
GB9704352D0 (en) * | 1997-03-03 | 1997-04-23 | Chiroscience Ltd | Levobupivacaine and its use |
US6034256A (en) | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
EP0903151A1 (en) * | 1997-09-22 | 1999-03-24 | ASTA Medica Aktiengesellschaft | Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms |
AU772807B2 (en) * | 1998-07-01 | 2004-05-06 | Warner-Lambert Company Llc | (-)-pseudoephedrine as a sympathomimetic drug |
ES2159209T3 (es) * | 1998-07-14 | 2001-09-16 | Alcon Lab Inc | Uso de acido 11-(3-dimetilaminopropiliden)-6,11-dihidrodibenz(b,e)oxepin-2-acetico y de sus sales farmaceuticamente aceptables para la fabricacion de un medicamento para el tratamiento de trastornos oftalmicos no alergicos y para la prevencion de neovascularizacion ocular. |
US6262066B1 (en) * | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
US20030087962A1 (en) | 1998-10-20 | 2003-05-08 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
AU1127700A (en) | 1998-10-20 | 2000-05-08 | Omeros Medical Systems, Inc. | Irrigation solution containing mapk inhibitors and their use for treating pain and inflammation |
US7973068B2 (en) | 1998-10-20 | 2011-07-05 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
AU1214800A (en) | 1998-10-21 | 2000-05-08 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain and inflammation |
DE69937070D1 (de) | 1998-11-05 | 2007-10-18 | Omeros Corp | Spüllösung und verfahren zur schmerzlinderung und entzündungshemmung |
WO2000035433A2 (en) | 1998-12-17 | 2000-06-22 | Alcon Laboratories, Inc. | Methods for the prevention and treatment of post-surgical complications |
JP2002544210A (ja) * | 1999-05-14 | 2002-12-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 炎症で仲介される感染症に対する抗炎症性治療方法 |
WO2001041550A2 (en) * | 1999-10-22 | 2001-06-14 | Transdermatech, Inc. | Topical anesthetic formulation |
EP1276475A2 (en) | 2000-04-28 | 2003-01-22 | Memorial Sloan-Kettering Cancer Center | Topical anesthetic/opioid formulations and uses thereof |
PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
AU2001280984A1 (en) * | 2000-07-28 | 2002-02-13 | Inspire Pharmaceuticals, Inc. | Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure |
JP2002161032A (ja) * | 2000-09-14 | 2002-06-04 | Taisho Pharmaceut Co Ltd | 粘膜適用組成物 |
CN1390124A (zh) * | 2000-09-20 | 2003-01-08 | 永光制药有限公司 | 近视眼的预防、治疗药 |
US20030191187A1 (en) | 2002-04-01 | 2003-10-09 | Lee Fang Yu | Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same |
CN103143022A (zh) | 2002-07-30 | 2013-06-12 | 奥默罗斯公司 | 眼科冲洗液及方法 |
CA2591706A1 (en) | 2004-12-22 | 2006-06-29 | Schering Corporation | Pharmaceutical formulations |
EP2262580A1 (en) | 2008-04-08 | 2010-12-22 | Fujifilm Manufacturing Europe BV | Composite membranes |
CA2764477A1 (en) | 2009-06-05 | 2010-12-09 | Aciex Therapeutics, Inc. | Ophthalmic formulations, methods of manufacture, and methods of using same |
WO2010141834A1 (en) | 2009-06-05 | 2010-12-09 | Aciex Therapeutics, Inc. | Ophthalmic formulations of fluticasone and methods of use |
AU2013201465B2 (en) | 2012-10-24 | 2016-03-03 | Rayner Surgical (Ireland) Limited | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
-
2003
- 2003-07-30 CN CN2012103206331A patent/CN103143022A/zh active Pending
- 2003-07-30 ES ES03772122T patent/ES2397574T3/es not_active Expired - Lifetime
- 2003-07-30 JP JP2004524225A patent/JP2006504661A/ja active Pending
- 2003-07-30 EP EP03772122A patent/EP1534313B1/en not_active Expired - Lifetime
- 2003-07-30 DK DK03772122.2T patent/DK1534313T3/da active
- 2003-07-30 SI SI200332231T patent/SI1534313T1/sl unknown
- 2003-07-30 US US10/630,626 patent/US20040072809A1/en not_active Abandoned
- 2003-07-30 PT PT37721222T patent/PT1534313E/pt unknown
- 2003-07-30 CA CA2493581A patent/CA2493581C/en not_active Expired - Lifetime
- 2003-07-30 AU AU2003261304A patent/AU2003261304A1/en not_active Abandoned
- 2003-07-30 WO PCT/US2003/023871 patent/WO2004010894A2/en active Application Filing
- 2003-07-30 CA CA2866848A patent/CA2866848C/en not_active Expired - Lifetime
- 2003-07-30 CN CN038233452A patent/CN1684701B/zh not_active Expired - Lifetime
- 2003-07-30 CN CNA2008101376172A patent/CN101327325A/zh active Pending
-
2006
- 2006-02-14 HK HK06101875.2A patent/HK1081455A1/xx not_active IP Right Cessation
-
2009
- 2009-12-11 AU AU2009248461A patent/AU2009248461B2/en not_active Expired
-
2010
- 2010-02-26 JP JP2010043527A patent/JP2010132696A/ja not_active Withdrawn
- 2010-05-05 US US12/799,981 patent/US8173707B2/en not_active Expired - Lifetime
- 2010-09-21 JP JP2010211424A patent/JP2011006475A/ja not_active Withdrawn
-
2012
- 2012-03-14 US US13/420,440 patent/US20130079344A1/en not_active Abandoned
- 2012-03-14 US US13/420,456 patent/US8586633B2/en not_active Expired - Lifetime
-
2013
- 2013-08-01 JP JP2013160106A patent/JP2013216705A/ja active Pending
- 2013-11-08 US US14/075,588 patent/US9399040B2/en not_active Expired - Lifetime
-
2014
- 2014-02-21 US US14/186,146 patent/US9278101B2/en not_active Expired - Fee Related
-
2015
- 2015-09-30 JP JP2015193350A patent/JP2016014055A/ja active Pending
- 2015-09-30 JP JP2015193351A patent/JP2016014056A/ja active Pending
- 2015-11-19 US US14/946,435 patent/US9585895B2/en not_active Expired - Lifetime
- 2015-12-16 CY CY2015055C patent/CY2015055I1/el unknown
- 2015-12-16 FR FR15C0090C patent/FR15C0090I2/fr active Active
- 2015-12-17 HU HUS1500069C patent/HUS1500069I1/hu unknown
- 2015-12-18 NL NL300784C patent/NL300784I2/nl unknown
- 2015-12-18 BE BE2015C078C patent/BE2015C078I2/nl unknown
- 2015-12-23 LU LU92923C patent/LU92923I2/xx unknown
-
2016
- 2016-06-30 US US15/198,208 patent/US20170100412A1/en not_active Abandoned
-
2017
- 2017-01-25 US US15/414,930 patent/US20170312295A1/en not_active Abandoned
- 2017-10-19 JP JP2017202579A patent/JP2018009033A/ja not_active Withdrawn
-
2018
- 2018-12-25 JP JP2018241032A patent/JP2019043965A/ja not_active Withdrawn
-
2020
- 2020-07-08 JP JP2020117688A patent/JP2020169205A/ja not_active Withdrawn
-
2021
- 2021-12-15 US US17/551,969 patent/US20220175797A1/en not_active Abandoned
-
2022
- 2022-07-15 JP JP2022114123A patent/JP2022132496A/ja active Pending
- 2022-07-15 JP JP2022114122A patent/JP2022132495A/ja active Pending
Patent Citations (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4550022A (en) * | 1981-10-05 | 1985-10-29 | Alcon Laboratories, Inc. | Tissue irrigating solution |
US4474811A (en) * | 1981-12-24 | 1984-10-02 | Kakenyaku Kako Co., Ltd. | Anti-inflammatory ophthalmic solution and process for preparing the same |
US4474751A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
US5212196A (en) * | 1986-10-21 | 1993-05-18 | Alcon Laboratories, Inc. | Control of post-surgical intraocular pressure using clonidine derivatives |
US4938970A (en) * | 1987-02-06 | 1990-07-03 | Hustead Robert E | Painless electrolyte solutions |
US5110493A (en) * | 1987-09-11 | 1992-05-05 | Syntex (U.S.A.) Inc. | Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant |
US4876250A (en) * | 1988-10-31 | 1989-10-24 | Alcon Laboratories, Inc. | Methods for controlling ocular hypertension with angiostatic steroids |
US5371078A (en) * | 1988-10-31 | 1994-12-06 | Alcon Laboratories, Inc. | Angiostatic steroids and methods and compositions for controlling ocular hypertension |
US5298487A (en) * | 1989-05-03 | 1994-03-29 | The Johns Hopkins University | Effective ophthalmic irrigation solution |
US5587175A (en) * | 1991-10-30 | 1996-12-24 | Mdv Technologies, Inc. | Medical uses of in situ formed gels |
US6117907A (en) * | 1993-04-14 | 2000-09-12 | Sher; Neal A. | Topical treatment of ocular pain after corneal surgery |
US5696091A (en) * | 1993-09-29 | 1997-12-09 | Alcon Laboratories, Inc. | Use of growth factor and antimetabolite combination to prevent or retard secondary cataract formation |
US5624893A (en) * | 1993-10-14 | 1997-04-29 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation |
US5523316A (en) * | 1994-06-23 | 1996-06-04 | Alcon Laboratories, Inc. | Intraocular irrigating solution containing agent for controlling IOP |
US5858017A (en) * | 1994-12-12 | 1999-01-12 | Omeros Medical Systems, Inc. | Urologic irrigation solution and method for inhibition of pain, inflammation and spasm |
US5800385A (en) * | 1994-12-12 | 1998-09-01 | Omeros Medical Systems, Inc. | Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis |
US5860950A (en) * | 1994-12-12 | 1999-01-19 | Omeros Medical Systems, Inc. | Arthroscopic irrigation solution and method for inhibition of pain and inflammation |
US5972326A (en) * | 1995-04-18 | 1999-10-26 | Galin; Miles A. | Controlled release of pharmaceuticals in the anterior chamber of the eye |
US5612027A (en) * | 1995-04-18 | 1997-03-18 | Galin; Miles A. | Controlled release of miotic and mydriatic drugs in the anterior chamber |
US5759532A (en) * | 1995-04-18 | 1998-06-02 | Galin; Miles A. | Controlled release of miotic and myriatic drugs in the anterior chamber |
US5767105A (en) * | 1995-05-03 | 1998-06-16 | Peyman; Gholam A. | Ocular solution |
US5798356A (en) * | 1995-08-07 | 1998-08-25 | Alcon Laboratories, Inc. | Angiostatic compounds |
US6254585B1 (en) * | 1995-12-12 | 2001-07-03 | Omeros Medical Systems, Inc. | Surgical irrigation solution and method for inhibition of pain and inflammation |
US6492332B1 (en) * | 1995-12-12 | 2002-12-10 | Omeros Corporation | Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation |
US6056715A (en) * | 1995-12-12 | 2000-05-02 | Omeros Medical Systems, Inc. | Surgical irrigation solution and method for inhibition of pain and inflammation |
US5820583A (en) * | 1995-12-12 | 1998-10-13 | Omeros Medical Systems, Inc. | Surgical irrigation solution and method for inhibition of pain and inflammation |
US6210394B1 (en) * | 1995-12-12 | 2001-04-03 | Omeros Medical Systems, Inc. | Surgical irrigation solution and method for inhibition of pain and inflammation |
US6645168B2 (en) * | 1995-12-12 | 2003-11-11 | Omeros Corporation | Arthroscopic irrigation solution and method for inhibition of pain and inflammation |
US6242447B1 (en) * | 1995-12-12 | 2001-06-05 | Omeros Medical Systems, Inc. | Surgical irrigation solution and method for inhibition of pain and inflammation |
US6420432B2 (en) * | 1995-12-12 | 2002-07-16 | Omeros Corporation | Surgical irrigation solution and method for inhibition of pain and inflammation |
US6261279B1 (en) * | 1995-12-12 | 2001-07-17 | Omeros Medical Systems, Inc. | Surgical irrigation solution and method for inhibition of pain and inflammation |
US6413961B1 (en) * | 1995-12-12 | 2002-07-02 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain and inflammation |
US6030974A (en) * | 1997-04-02 | 2000-02-29 | The Regents Of The University Of California | Method of anesthesia |
US5811446A (en) * | 1997-04-18 | 1998-09-22 | Cytos Pharmaceuticals Llc | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor |
US6495598B1 (en) * | 1997-04-22 | 2002-12-17 | Ophtecs Corporation | Perfusate preparation for ophthalmic operation |
US6280745B1 (en) * | 1997-12-23 | 2001-08-28 | Alliance Pharmaceutical Corp. | Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions |
US6395746B1 (en) * | 1998-09-30 | 2002-05-28 | Alcon Manufacturing, Ltd. | Methods of treating ophthalmic, otic and nasal infections and attendant inflammation |
US6218428B1 (en) * | 2000-04-28 | 2001-04-17 | Emil Chynn | Ophthalmic composition |
US20020128267A1 (en) * | 2000-07-13 | 2002-09-12 | Rebanta Bandyopadhyay | Method of using COX-2 inhibitors in the treatment and prevention of ocular COX-2 mediated disorders |
US20020071874A1 (en) * | 2000-07-14 | 2002-06-13 | Allergan Sales, Inc. | Compositions containing therapeutically active components having enhanced solubility |
US6562873B2 (en) * | 2000-07-14 | 2003-05-13 | Allergan, Inc. | Compositions containing therapeutically active components having enhanced solubility |
US20020183279A1 (en) * | 2001-04-18 | 2002-12-05 | Koichiro Tanaka | Pharmaceutical composition containing viscoelastic substance and medication |
US20030017199A1 (en) * | 2001-05-03 | 2003-01-23 | Woodward David F. | Compositions having enhanced pharmacokinetic characteristics |
Cited By (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9399040B2 (en) | 2002-07-30 | 2016-07-26 | Omeros Corporation | Ophthalmologic irrigation solutions and method |
US9278101B2 (en) | 2002-07-30 | 2016-03-08 | Omeros Corporation | Ophthalmologic irrigation solutions and method |
US9585895B2 (en) | 2002-07-30 | 2017-03-07 | Omeros Corporation | Ophthalmologic irrigation solutions and method |
US20060183698A1 (en) * | 2004-06-07 | 2006-08-17 | Ista Pharmaceuticals, Inc. | Ophthalmic formulations and uses thereof |
US8748402B2 (en) | 2004-06-07 | 2014-06-10 | Bausch & Lomb Pharma Holdings Corp. | Ophthalmic formulations and uses thereof |
US8372814B2 (en) | 2004-06-07 | 2013-02-12 | Ista Pharmaceuticals, Inc. | Ophthalmic formulations and uses thereof |
EP2457585A1 (en) | 2004-06-10 | 2012-05-30 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP2465535A1 (en) | 2004-06-10 | 2012-06-20 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP3047858A1 (en) | 2004-06-10 | 2016-07-27 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
EP3530288A2 (en) | 2004-06-10 | 2019-08-28 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
EP2382991A1 (en) | 2004-06-10 | 2011-11-02 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP2386316A1 (en) | 2004-06-10 | 2011-11-16 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP2386317A1 (en) | 2004-06-10 | 2011-11-16 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP2386315A1 (en) | 2004-06-10 | 2011-11-16 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP2392350A1 (en) | 2004-06-10 | 2011-12-07 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP2446901A1 (en) | 2004-06-10 | 2012-05-02 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP2446902A1 (en) | 2004-06-10 | 2012-05-02 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP2446900A1 (en) | 2004-06-10 | 2012-05-02 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP2465534A1 (en) | 2004-06-10 | 2012-06-20 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP2460537A1 (en) | 2004-06-10 | 2012-06-06 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US9289399B2 (en) * | 2005-03-09 | 2016-03-22 | Laboratoires Thea | Ophthalmologic compositions and use mode thereof |
US20120220637A1 (en) * | 2005-03-09 | 2012-08-30 | Walild Khatib | Ophthalmologic Compositions And Use Mode Thereof |
US20080194649A1 (en) * | 2005-03-09 | 2008-08-14 | Laboratoires Thea | Ophthalmologic Compositions And Use Mode Thereof |
US20110028516A1 (en) * | 2005-08-26 | 2011-02-03 | Fu-Pao Tsao | Stabilized and preserved ketoifen ophthalmic compositions |
US20120157496A1 (en) * | 2005-08-26 | 2012-06-21 | Fu-Pao Tsao | Stabilized and preserved ketotifen ophthalmic compositions |
EP3067067A1 (en) | 2006-04-03 | 2016-09-14 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
WO2007117996A2 (en) | 2006-04-03 | 2007-10-18 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
US20080153818A1 (en) * | 2006-12-21 | 2008-06-26 | Bingaman David P | Methods for preventing inflammation during surgery |
US8389014B2 (en) * | 2006-12-22 | 2013-03-05 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of ophthalmic drugs |
US20100069482A1 (en) * | 2006-12-22 | 2010-03-18 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of ophthalmic drugs |
WO2008151288A2 (en) * | 2007-06-05 | 2008-12-11 | Xenon Pharmaceuticals Inc. | Aromatic and heteroaromatic compounds useful in treating iron disorders |
WO2008151288A3 (en) * | 2007-06-05 | 2009-09-24 | Xenon Pharmaceuticals Inc. | Aromatic and heteroaromatic compounds useful in treating iron disorders |
US10463677B2 (en) | 2008-11-07 | 2019-11-05 | Cydex Pharmaceuticals, Inc. | Composition containing sulfoalkyl ether cyclodextrin and latanoprost |
WO2010053487A1 (en) * | 2008-11-07 | 2010-05-14 | Cydex Pharmaceuticals, Inc. | Composition containing sulfoalkyl ether cyclodextrin and latanoprost |
US20100240624A1 (en) * | 2009-03-17 | 2010-09-23 | Aciex Therapeutics, Inc. | Ophthalmic Formulations of Ketotifen and Methods of Use |
EP3150635A2 (en) | 2009-10-16 | 2017-04-05 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
EP3287142A1 (en) | 2011-04-08 | 2018-02-28 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
US8951522B2 (en) | 2011-04-08 | 2015-02-10 | University Of Leicester | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP3964233A1 (en) | 2011-04-08 | 2022-03-09 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
WO2012139081A2 (en) | 2011-04-08 | 2012-10-11 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US10059776B2 (en) | 2011-04-08 | 2018-08-28 | Omerus Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US10202465B2 (en) | 2011-04-08 | 2019-02-12 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
CN108721210A (zh) * | 2012-10-24 | 2018-11-02 | 奥默罗斯公司 | 稳定的不含防腐剂的瞳孔散大剂和用于注射的抗炎溶液 |
US9066856B2 (en) * | 2012-10-24 | 2015-06-30 | Omeros Corporation | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
US9486406B2 (en) | 2012-10-24 | 2016-11-08 | Omeros Corporation | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
US9855246B2 (en) | 2012-10-24 | 2018-01-02 | Omeros Corporation | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
US20140235691A1 (en) * | 2012-10-24 | 2014-08-21 | Omeros Corporation | Stable Preservative-free Mydriatic and Anti-inflammatory Solutions for Injection |
US9504691B2 (en) * | 2012-12-06 | 2016-11-29 | Alcon Research, Ltd. | Finafloxacin suspension compositions |
US20140162990A1 (en) * | 2012-12-06 | 2014-06-12 | Alcon Research, Ltd. | Finafloxacin suspension compositions |
US10010483B2 (en) | 2013-08-20 | 2018-07-03 | Anutra Medical, Inc. | Cassette assembly for syringe fill system |
US9393177B2 (en) | 2013-08-20 | 2016-07-19 | Anutra Medical, Inc. | Cassette assembly for syringe fill system |
US10010482B2 (en) | 2013-08-20 | 2018-07-03 | Anutra Medical, Inc. | Syringe fill system and method |
US9579257B2 (en) | 2013-08-20 | 2017-02-28 | Anutra Medical, Inc. | Haptic feedback and audible output syringe |
US9387151B2 (en) | 2013-08-20 | 2016-07-12 | Anutra Medical, Inc. | Syringe fill system and method |
US11045432B2 (en) | 2013-10-03 | 2021-06-29 | Harrow Ip, Llc | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof |
USD763433S1 (en) | 2014-06-06 | 2016-08-09 | Anutra Medical, Inc. | Delivery system cassette |
USD750768S1 (en) | 2014-06-06 | 2016-03-01 | Anutra Medical, Inc. | Fluid administration syringe |
USD774182S1 (en) | 2014-06-06 | 2016-12-13 | Anutra Medical, Inc. | Anesthetic delivery device |
US11234965B2 (en) | 2014-12-01 | 2022-02-01 | Omeros Corporation | Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions |
US10695311B2 (en) | 2016-06-03 | 2020-06-30 | Jörg H. Krumeich | Solution for ophthalmology |
US10220012B2 (en) * | 2016-06-03 | 2019-03-05 | Joerg H. KRUMEICH | Solution for ophthalmology |
US11390654B2 (en) * | 2016-09-02 | 2022-07-19 | Christopher Joseph Soares | Use of CGRP receptor antagonists in neuroprotection and neurological disorders |
US11395825B2 (en) | 2017-05-04 | 2022-07-26 | Ocular Science, Inc. | Compositions and methods for treating eyes and methods of preparation |
US11071724B2 (en) | 2019-05-17 | 2021-07-27 | Ocular Science, Inc. | Compositions and methods for treating presbyopia |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9585895B2 (en) | Ophthalmologic irrigation solutions and method | |
EP2301562B1 (en) | Irrigation solution and method for inhibition of pain, inflammation and spasm | |
KR100517210B1 (ko) | 통증,염증및경련억제용관주용액 | |
AU2018200887B2 (en) | Ophthalmologic irrigation solutions and method | |
AU2013202330A1 (en) | Ophthalmologic irrigation solutions and method | |
KR20080068881A (ko) | 안압 강하제인 숙신이미드 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: OMEROS CORPORATION, WASHINGTON Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DEMOPULOS, GREGORY A.;PALMER, PAMELA PIERCE;HERZ, JEFFREY M.;REEL/FRAME:014719/0624;SIGNING DATES FROM 20030922 TO 20031008 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |